Anzeige
Mehr »
Login
Samstag, 23.11.2024 Börsentäglich über 12.000 News von 677 internationalen Medien
Microsofts, Googles und Amazons nukleares Wettrennen macht diese Uranaktie zu einem Muss!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3DWEJ | ISIN: US15117N6022 | Ticker-Symbol: CBO
Tradegate
22.11.24
17:59 Uhr
0,795 Euro
+0,015
+1,92 %
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
IMUNON INC Chart 1 Jahr
5-Tage-Chart
IMUNON INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,7600,80011:04
0,7650,80022.11.

Aktuelle News zur IMUNON Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
07.11.Imunon, Inc.: IMUNON Presents Positive Data from Phase 2 OVATION 2 Clinical Trial of IMNN-001 in Advanced Ovarian Cancer at SITC 39th Annual Meeting101IMNN-001 immunotherapy plus standard-of-care chemotherapy resulted in 35% improvement in overall survival and 25% improvement in progression-free survival versus standard-of-care alone Treatment was...
► Artikel lesen
07.11.Imunon, Inc.: IMUNON Reports Third Quarter 2024 Financial Results and Provides Business Updates121Conference call today at 11:00 a.m. ET LAWRENCEVILLE, N.J., Nov. 07, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in late-stage development with its DNA-mediated...
► Artikel lesen
07.11.Imunon, Inc. - 8-K, Current Report-
07.11.Imunon, Inc. - 10-Q, Quarterly Report-
06.11.Imunon Q3 2024 Earnings Preview3
06.11.Earnings Outlook For Imunon1
30.10.Imunon, Inc.: IMUNON to Present Phase 2 Data of IMNN-001 in Treatment of Newly Diagnosed Ovarian Cancer at SITC 39th Annual Meeting2
07.10.Imunon, Inc. - 8-K, Current Report1
IMUNON Aktie jetzt für 0€ handeln
07.10.Imunon, Inc.: IMUNON Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)108LAWRENCEVILLE, N.J., Oct. 07, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN) (the "Company"), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, today announced...
► Artikel lesen
25.09.Imunon (NASDAQ:IMNN) Upgraded by EF Hutton Acquisition Co. I to "Strong-Buy"1
23.09.EF Hutton sets stock target on Imunon, initiates with buy rating2
20.09.Imunon, Inc. - S-1/A, General form for registration of securities4
03.09.Imunon, Inc. - 8-K, Current Report3
29.08.Imunon files to sell up to 5M shares5
29.08.Imunon, Inc. - S-1, General form for registration of securities-
29.08.Imunon, Inc. - S-8, Securities to be offered to employees in employee benefit plans1
28.08.Imunon, Inc.: IMUNON to Host R&D Day on September 18th1
16.08.Imunon CEO buys $24,500 in company stock at $0.98 per share3
16.08.Imunon executive chairman buys $25,750 in company stock2
15.08.Earnings call: Imunon reports Q2 financials, advances in cancer trials2
Seite:  Weiter >>
48 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,3